2021 Attendee Profile

**List updated as of January 19, 2021

 

TitleCompany
Exec DirACADIA Pharmaceuticals Inc
Bus Dev MgrAgilent Technologies LDA UK Ltd
Dir CMC Regulatory AffairsAkcea Therapeutics
Dir Process & Analytical SciencesAlnylam Pharmaceuticals
Distinguished Scientist & Sr VP Innovation ChemAlnylam Pharmaceuticals
ScientistAlnylam Pharmaceuticals
ScientistAlnylam Pharmaceuticals
Sr ScientistAmgen Inc
Sr Research FellowArcturus Therapeutics Inc
VP & HeadAro Biotherapeutics
Chief Commercial OfficerArrowhead Pharmaceuticals Inc
Sr ScientistArrowhead Pharmaceuticals Inc
Principal Scientist & ExpertAsahi Kasei Pharma Co Ltd
Sr ScientistAstellas Innovation Mgmt LLC
CSOAvidity Biosciences LLC
Exec DirBeth Israel Deaconess Medical Ctr
Deputy HeadBfArM
Assoc Dir ASO Process Engineering & MfgBiogen
Postdoctoral ScientistBiogen
Dir Chemical Dev & MfgBioMarin Pharmaceutical Inc
Exec DirBioMarin Pharmaceutical Inc
Formulation ScientistBioMarin Pharmaceutical Inc
Mgr Chemical Dev & MfgBioMarin Pharmaceutical Inc
Principal ScientistBioMarin Pharmaceutical Inc
Scientist IIBioMarin Pharmaceutical Inc
Assoc Prof MedicineBrigham & Womens Hospital
Principal ScientistBristol Myers Squibb Co
Sr Research InvestigatorBristol Myers Squibb Co
Scientist & MgrCardior Pharmaceuticals GmbH
Chief of OperationsChemGenes Corp
PrincipalCMC Tyndall Consultant
VP Bus DevDrugScan
Dir Preclinical Drug SafetyEisai Inc
Distinguished ScientistEisai Inc
Graduate StudentEmail Address Only
Assoc DirGeron Corp
VPGeron Corp
Assoc Dir Tech SvcsGlaxoSmithKline
DirGlaxoSmithKline
Dir Chemistry DevGlaxoSmithKline
ScientistGlaxoSmithKline
Senior ManagerGlaxoSmithKline
Sr Dir Chemical DevGlaxoSmithKline
Assoc MgrGreen Cross R&D Ctr
Research Scientist IIH Lee Moffitt Cancer Ctr & Research Institute
HeadHansoh Bio LLC
HeadHansoh Bio LLC
VPHitGen Inc
Chemist IIHorizon Discovery
Business Dev MgrHybridize Therapeutics BV
Principle ScientistImnewrun Biosciences Inc
CSOIntellia Therapeutics Inc
ScientistIntellia Therapeutics Inc
Dir Translational Research & ChemistryinviCRO LLC
Exec VP Drug DevIonis Pharmaceuticals Inc
VP & HeadIonis Pharmaceuticals Inc
VP Analytical & Process Dev ChemistryIonis Pharmaceuticals Inc
Graduate StudentJW Goethe Univ
Principal ScientistKairos Bioconsulting
CEOKorro Bio Inc
Sr ScientistLEO Pharma Inc
OncologistLondon Regional Cancer Ctr
Assoc ProfMaxillofacial Surgery Svcs MFSS
PrincipalML Consult LLC
CSOModerna
Section ChiefNCNP
Researcher & Project MgrNIH NCATS
Sr InvestigatorNIH NIA
Research ChemistNIST
Grp LeaderNITTO DENKO Avecia Inc
Sr Research ScientistNovo Nordisk Research Ctr
Principal ScientistNovo Nordisk Research Ctr China
Exec Dir & Global Lead Internal MedicinePfizer Inc
MgrPfizer Inc
Sr Principal ScientistPfizer Inc
Dir Bus Dev & Head SalesPolyPeptide Labs Inc
HeadPolyPeptide Labs Inc
Product MgrPolyPeptide Labs Inc
CSOQ State Biosciences
Dir Cell BiologyQ State Biosciences
Dir Chemistry & Project MgrQ State Biosciences
Sr ScientistQ State Biosciences
Sr ScientistQ State Biosciences
VP of Scientific AffairsQ State Biosciences
CSOQuark Pharmaceuticals
Principal ScientistRoche Innovation Ctr Copenhagen
Sr Dir Alliance MgmtSanofi Germany GmbH
Chair & ProfScripps Research Institute
CTOSirnaomics Inc
Sr ScientistSirnaomics Inc
ScientistStoke Therapeutics
R&D MgrSylentis SA
PartnerSynoloStats LLC
Assoc DirTakeda Pharmaceutical Co Ltd
Assoc DirTakeda Pharmaceutical Co Ltd
Principal ResearcherTakeda Pharmaceutical Co Ltd
Principal ScientistTakeda Pharmaceutical Co Ltd
Assoc Scientific FellowTakeda Pharmaceuticals Inc
ScientistTCR2 Therapeutics Inc
VPTriLink BioTechnologies
Prof & Dir ChemBioPharmUniv of Bordeaux II
ProfUniv of Massachusetts
Advisory Board MemberUniv of Pennsylvania
Assoc ProfUniv of Tokyo
Principal Application ChemistWaters Corp
ScientistWAVE Life Sciences
President & CEOWings Therapeutics

 

 

2020 Event Features:

OPT Congress 2020 Features:

The Oligonucleotide & Precision Therapeutics Congress 2020 brought record attendance last year, with over 250+ professionals from the oligonucleotide discovery and development field. With 2 expanded conferences, poster viewing sessions, an educational short course, exhibit hall and networking opportunities, and several breakout discussions, the event proved that we can still connect and engage the same way we do at in-person events. We hope you will join us in March 2021.

 


2019 Attendee Profile

OPT Congress 2019
Attended by more than 130 unique companies

The Fourth Annual “Oligonucleotide & Precision Therapeutics” (OPT Congress) was held March 26-28, 2019 at the Hyatt Regency Cambridge, in Cambridge, Massachusetts.

More than 200 industry leaders from 14 different countries joined the 2-day program dedicated to Oligonucleotide Discovery & Delivery, CMC and Regulatory Strategies. In addition, we delivered two in-depth symposiums focusing on Drug Discovery for Rare Diseases and New Frontiers in Gene Editing and Repair. NEW for 2020 we will be assessing the impact of AI on drug discovery.

The congress participation was represented well with 55% attended by executives. With more than 65% of the audience from biotech, another 15% from pharma, and the event represented by 130+ unique organizations, this event will continue to gather a diverse body of attendees from around the world to network, share ideas, and discuss cutting-edge science and technology.

Company Type
Title Type


2019 Event Features

  • 200+ Participants
  • 2 Conferences
  • 2 Symposium
  • Dinner Courses
  • Dedicated Poster Viewing Sessions
  • Dedicated Exhibit Hall Hours and Networking Functions

Hear what a few people had to say about OPT Congress 2019

“Well balanced content, perfectly executed logistics.”
     Dmitry S., PhD, CTO, Sirnaomics

“The scientific quality of the presentations was very high and the opportunities for networking were excellent.”
Ekkehard L., PhD, Senior Director, R&D Alliance Management, Sanofi

With special thanks to our Executive Advisory Board who help to shape the program:

  • Arthur Levin, PhD, Executive Vice President, Research and Development, Avidity Biosciences
  • Muthiah (Mano) Manoharan, PhD, Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals
  • Dmitry Samarsky, PhD, CTO, Sirnaomics
  • Lubo Nechev, PhD, Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals
video
photo


RNA Targeting with Antisense Oligonucleotides: Present and Future
Geary_RichardRichard S. Geary, PhD, Senior Vice President, Development, Ionis Pharmaceuticals

Key Contacts

For content and speaker suggestions
Oligonucleotide Discovery and Development

Gemma Smith
Senior Director, Conferences
Cambridge Healthtech Institute
T: +447754.518.131
E: gsmith@cambridgeinnovationinstitute.com

For partnering and sponsorship information:

Shannon Kresge 
Business Development Manager 
781-972-1343
E: skresge@healthtech.com

For media partnerships:

Dan Miller, Marketing Manager
Cambridge Healthtech Institute
T: (+1) 781.972.5492
E: dmiller@healthtech.com



Register!